Cancer Biotech Kolltan Pharmaceuticals Pulls $86M IPO
Venture capital- and private equity-backed Kolltan Pharmaceuticals Inc., an early stage biotech developing cancer fighting drugs, on Wednesday pulled plans for an $86.25 million public offering, according to a filing with the...To view the full article, register now.
Already a subscriber? Click here to view full article